stockrowIDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
Follow IDYA
Alert me
IDEAYA Biosciences, Inc. (IDYA) Return on assets
IDEAYA Biosciences, Inc.'s return on assets over the twelve months to 30 September 2026 was −35.0%, down 24.8 percentage points from fiscal 2025 (−10.2%). Over the past ten years it has ranged from −71.2% (fiscal 2018) to −10.2% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −10.2% | 20.77 |
| FY2024 | −31.0% | (9.17) |
| FY2023 | −21.8% | (6.53) |
| FY2022 | −15.3% | (0.61) |
| FY2021 | −14.6% | 2.13 |
| FY2020 | −16.8% | 23.29 |
| FY2019 | −40.1% | 31.09 |
| FY2018 | −71.2% | (50.34) |
| FY2017 | −20.8% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| BEAM Beam Therapeutics Inc. compare | −8.40% |
| ELVN Enliven Therapeutics, Inc. compare | −15.0% |
| DNLI Denali Therapeutics Inc. compare | −27.2% |
| IDYA IDEAYA Biosciences, Inc. | −35.0% |
| CELC Celcuity, Inc. compare | −44.8% |
| VRDN Viridian Therapeutics, Inc. compare | −56.5% |
| DYN Dyne Therapeutics, Inc. compare | −60.3% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −135.0% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on IDYA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement